Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
15 08 2022
15 08 2022
Historique:
received:
05
01
2022
accepted:
26
07
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
18
8
2022
Statut:
epublish
Résumé
Weight regain after weight loss remains a major challenge in obesity treatment and may involve alteration of eating and sedentary behavior after weight loss. In this randomized, controlled, double-blind trial, adults with obesity were randomized, in a 1:1:1:1 ratio stratified by sex and age group (<40 years and ≥40 years), to one-year weight loss maintenance with exercise, the GLP-1 receptor agonist liraglutide, or the combination, as compared with placebo, after low-calorie diet-induced weight loss. Primary outcome was change in body weight, which has been published. Here, we investigated the effects of weight loss maintenance with exercise, liraglutide, or the combination on weight loss-induced changes in the pre-specified explorative outcomes, eating and sedentary behavior in 130 participants who completed the trial according to the study protocol (exercise (n = 26), liraglutide (n = 36), combination (n = 29), and placebo (n = 39)). One year after weight loss, the placebo group had decreased postprandial appetite suppression score by 14%, and increased sedentary time by 31 min/day and regained weight. Liraglutide prevented the decrease in postprandial appetite suppression score compared with placebo (0% vs. -14%; P = 0.023) and maintained weight loss. Exercise after weight loss did not increase appetite or sedentary behavior compared with placebo, despite increased exercise energy expenditure and maintained weight loss. The combination of exercise and liraglutide increased cognitive restraint score (13% vs. -9%; P = 0.042), reflecting a conscious restriction of food intake, and decreased sedentary time by 41 min/day (-10 vs. 31 min/day; 95%CI, -82.3 to -0.2; P = 0.049) compared with placebo, which may have facilitated the additional weight loss. Targeting both eating and sedentary behavior could be the most effective for preventing weight regain.Trial registration: EudraCT number, 2015-005585-32; clinicaltrials.gov number, NCT04122716.
Identifiants
pubmed: 35970829
doi: 10.1038/s41467-022-32307-y
pii: 10.1038/s41467-022-32307-y
pmc: PMC9378667
doi:
Substances chimiques
Hypoglycemic Agents
0
Liraglutide
839I73S42A
Banques de données
ClinicalTrials.gov
['NCT04122716']
EudraCT
['2015-005585-32']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4770Informations de copyright
© 2022. The Author(s).
Références
Res Q Exerc Sport. 2000 Jun;71 Suppl 2:114-20
pubmed: 25680021
Eur J Endocrinol. 2016 Jun;174(6):775-84
pubmed: 26976129
Dis Model Mech. 2012 Sep;5(5):608-13
pubmed: 22915022
Curr Obes Rep. 2020 Jun;9(2):63-80
pubmed: 32297126
Int J Obes (Lond). 2020 Feb;44(2):353-361
pubmed: 30926955
PLoS One. 2013 Apr 23;8(4):e61691
pubmed: 23626718
Am J Clin Nutr. 2004 Jan;79(1):62-9
pubmed: 14684398
Obesity (Silver Spring). 2016 Nov;24(11):2289-2295
pubmed: 27804272
Obes Facts. 2017;10(6):633-647
pubmed: 29207396
PLoS One. 2017 Feb 1;12(2):e0169649
pubmed: 28146576
Physiol Behav. 2004 Aug;82(1):21-5
pubmed: 15234585
Prev Med. 2009 Aug;49(1):32-8
pubmed: 19406146
Appetite. 2014 Nov;82:78-84
pubmed: 25049138
Cell Metab. 2018 Jul 03;28(1):23-32.e3
pubmed: 29861388
N Engl J Med. 2011 Oct 27;365(17):1597-604
pubmed: 22029981
Appetite. 2010 Dec;55(3):648-55
pubmed: 20870002
J Clin Invest. 1998 Feb 1;101(3):515-20
pubmed: 9449682
Int J Obes (Lond). 2019 Jul;43(7):1466-1474
pubmed: 30659256
Control Clin Trials. 2000 Jun;21(3):167-89
pubmed: 10822117
Med Sci Sports Exerc. 2013 Aug;45(8):1600-9
pubmed: 23470300
Am J Clin Nutr. 1989 Dec;50(6):1314-23
pubmed: 2596423
J Nutr. 2004 Sep;134(9):2372-80
pubmed: 15333731
N Engl J Med. 2021 May 6;384(18):1719-1730
pubmed: 33951361
Obes Rev. 2020 Jan;21(1):e12949
pubmed: 31675146
Int J Obes (Lond). 2014 Jun;38(6):784-93
pubmed: 23999198
Am J Clin Nutr. 2009 Oct;90(4):921-7
pubmed: 19675105
Int J Behav Nutr Phys Act. 2009 Jul 17;6:41
pubmed: 19615047
Am J Clin Nutr. 2008 Oct;88(4):906-12
pubmed: 18842775
Br J Sports Med. 2020 Dec;54(24):1451-1462
pubmed: 33239350
Med Sci Sports Exerc. 1999 Nov;31(11 Suppl):S534-41
pubmed: 10593524
Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48
pubmed: 10702749
Am J Epidemiol. 2014 Mar 15;179(6):781-90
pubmed: 24500862
J Appl Physiol (1985). 2014 Oct 1;117(7):738-44
pubmed: 25103964
Int J Obes (Lond). 2018 Aug;42(8):1489-1499
pubmed: 29930313
BMJ Open. 2019 Nov 2;9(11):e031431
pubmed: 31678947
Am J Clin Nutr. 1956 Mar-Apr;4(2):169-75
pubmed: 13302165
JAMA. 2003 Apr 9;289(14):1785-91
pubmed: 12684356
Appetite. 2011 Dec;57(3):722-8
pubmed: 21896296
Diabetes Obes Metab. 2017 Sep;19(9):1242-1251
pubmed: 28266779
Med Clin North Am. 2018 Jan;102(1):183-197
pubmed: 29156185
N Engl J Med. 1995 Mar 9;332(10):621-8
pubmed: 7632212
Diabetes Res Clin Pract. 2012 Aug;97(2):258-66
pubmed: 22446097
PLoS One. 2009;4(2):e4377
pubmed: 19198647